HOOKIPA Pharma Announced Its Final Pivotal Phase 2/3 Trial Design For HB-200 In Combination With Pembrolizumab Based On Alignment With The FDA
HOOKIPA Pharma 宣布了其基于与 FDA 一致性的 HB-200 与 Pembrolizumab 联合使用的最终关键的 2/3 阶段试验设计
HOOKIPA Pharma Announced Its Final Pivotal Phase 2/3 Trial Design For HB-200 In Combination With Pembrolizumab Based On Alignment With The FDA
HOOKIPA Pharma 宣布了其基于与 FDA 一致性的 HB-200 与 Pembrolizumab 联合使用的最终关键的 2/3 阶段试验设计
使用浏览器的分享功能,分享给你的好友吧